全文获取类型
收费全文 | 2453篇 |
免费 | 184篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 94篇 |
妇产科学 | 52篇 |
基础医学 | 310篇 |
口腔科学 | 25篇 |
临床医学 | 229篇 |
内科学 | 645篇 |
皮肤病学 | 54篇 |
神经病学 | 143篇 |
特种医学 | 48篇 |
外科学 | 480篇 |
综合类 | 24篇 |
预防医学 | 136篇 |
眼科学 | 14篇 |
药学 | 181篇 |
中国医学 | 7篇 |
肿瘤学 | 189篇 |
出版年
2023年 | 45篇 |
2022年 | 59篇 |
2021年 | 98篇 |
2020年 | 47篇 |
2019年 | 54篇 |
2018年 | 74篇 |
2017年 | 60篇 |
2016年 | 57篇 |
2015年 | 56篇 |
2014年 | 96篇 |
2013年 | 88篇 |
2012年 | 123篇 |
2011年 | 156篇 |
2010年 | 78篇 |
2009年 | 88篇 |
2008年 | 140篇 |
2007年 | 124篇 |
2006年 | 112篇 |
2005年 | 94篇 |
2004年 | 106篇 |
2003年 | 101篇 |
2002年 | 90篇 |
2001年 | 61篇 |
2000年 | 70篇 |
1999年 | 60篇 |
1998年 | 27篇 |
1997年 | 10篇 |
1996年 | 18篇 |
1995年 | 20篇 |
1994年 | 15篇 |
1993年 | 7篇 |
1992年 | 41篇 |
1991年 | 32篇 |
1990年 | 39篇 |
1989年 | 48篇 |
1988年 | 28篇 |
1987年 | 32篇 |
1986年 | 29篇 |
1985年 | 22篇 |
1984年 | 14篇 |
1983年 | 21篇 |
1982年 | 6篇 |
1981年 | 7篇 |
1980年 | 11篇 |
1979年 | 18篇 |
1978年 | 7篇 |
1975年 | 7篇 |
1974年 | 7篇 |
1971年 | 6篇 |
1970年 | 5篇 |
排序方式: 共有2649条查询结果,搜索用时 31 毫秒
41.
Hironori Tsujimoto Hiroyuki Horiguchi Risa Takahata Satoshi Ono Yoshihisa Yaguchi Shinsuke Nomura Nozomi Ito Manabu Harada Hiromi Nagata Yusuke Ishibashi Keita Kouzu Satoshi Tsuchiya Yujiro Itazaki Seiichiro Fujishima Yoji Kishi Hideki Ueno 《Journal of gastroenterology and hepatology》2020,35(5):788-794
42.
Risa Konishi Ryota Tanaka Sae Inoue Yuki Ichimura Toshifumi Nomura Naoko Okiyama 《The Journal of dermatology》2022,49(1):118-123
Dermatomyositis, an idiopathic inflammatory myopathy, is characterized by cutaneous itchy manifestations, which are frequently refractory and recurrent even after intensive immunosuppressive treatments. To evaluate the effectiveness and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in treating skin-dominant dermatomyositis in which myositis and interstitial lung disease are absent or in remission, we performed this prospective, single-arm, interventional study. A total of five Japanese patients (one male and four females, median [range] age, 64 [37–71] years) with refractory dermatomyositis-associated cutaneous manifestations were recruited and treated with a 12-week course of oral apremilast. Among five enrolled patients, three experienced diarrhea with full-dose apremilast (30 mg twice daily), two of whom withdrew from the study and recovered quickly afterwards. A total of three evaluable female patients (median [range] age, 65 [64–71] years) received apremilast treatment for 12 weeks. A 39.4% reduction from baseline Cutaneous Dermatomyositis Disease Area and Severity Index total activity score, but not the damage score, at week 12 was observed in all three patients. Visual analog scale of itching, and quality of life by Dermatology Life Quality Index were slightly improved in one and two apremilast-treated patients, respectively. As apremilast was effective, with expected and recoverable digestive adverse events (diarrhea), in patients with refractory and recurrent dermatomyositis-associated cutaneous manifestations in this first phase Ib study, it can be suggested as a possible treatment when aggressive immunosuppressive therapies with high-dose systemic corticosteroid and/or immunosuppressive agents for other manifestations, myositis, and interstitial lung disease, are not required. 相似文献
43.
Koji Kimura Risa Takayanagi Haruko Yokoyama Yasuhiko Yamada 《Rheumatology international》2012,32(1):145-150
In Japan, the recommended dosage regimens of infliximab (IFX) for treatment of rheumatoid arthritis (RA) and Crohn’s disease
(CD) are different. However, the differences have not been analyzed theoretically. In a previous study, we constructed a pharmacokinetic–pharmacodynamic
model to investigate the effects of IFX for CD and found it useful to establish a rational dosage regimen of IFX for individual
patients with CD. In the present study, we investigated whether the theory-based model could be used for cases of RA and also
used it to evaluate the validity of the dosage regimen. The results obtained with our model were in good agreement with observed
tender joint count (TJC) ratio data, which was considered to show the validity of our analysis. Thus, we concluded that the
model could be used for patients with RA. Furthermore, a second administration of IFX given 2 weeks after the first infusion
was important to achieve remission in the early stage of RA. We also compared the estimated pharmacodynamic parameters of
RA with those of CD. The elimination rate constant of inflammation in RA was greater than that in CD, suggesting that the
recovery from inflammation in RA is faster than that in CD, and indicating a reason for the difference in dosage between RA
and CD. In conclusion, use of our model in light of the individual quantitative factor of tumor necrosis factor (TNF)-α allows
establishment of IFX dosage regimens for individual patients. 相似文献
44.
Immunohistochemical expression profiles of solute carrier transporters in alpha‐fetoprotein‐producing gastric cancer
下载免费PDF全文
![点击此处可从《Histopathology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
45.
Risa Chaisuparat Somsri Rojanawatsirivej Somchai Yodsanga 《Pathology oncology research : POR》2013,19(2):189-193
Ribosomal protein S6 (RPS6), a downstream effector of the mammalian target of rapamycin pathway (mTOR), is activated in many cancers including oral squamous cell carcinoma (OSCC). However, the role of RPS6 in the progression of potentially malignant disorders (or premalignant lesions) to OSCC is unknown. The purpose of this study was to examine the expression of RPS6 in epithelial dysplasia and OSCC to determine the association of RPS6 in tumor progression. In our study, an immunohistochemical analysis of RPS6 was performed on tissue microarrays containing 30 control samples, 15 epithelial dysplasia cases, and 53 OSCC cases. Correlations between the clinicopathologic features of OSCC and RPS6 expression were analyzed using the Chi-square test. We found RPS6 phosphorylation (p-RPS6) in 15/30 (50 %) control normal oral mucosa samples, 15/15 (100 %) epithelial dysplasia cases, and 47/53 (88.68 %) OSCC cases. The frequency of p-RPS6 in epithelial dysplasia or OSCC showed a statistically significant difference compared to control (P?<?0.001). However, there were no significant correlations between p-RPS6 and the clinicopathologic features of OSCC. Our findings suggest that RPS6 activation is associated with the early events of tumor progression, suggesting p-RPS6 as a potential marker for early detection of oral cancer. 相似文献
46.
Junko Daito Yoshinori Harada Ping Dai Yoshihisa Yamaoka Risa Tamagawa-?Mineoka Norito Katoh Tetsuro Takamatsu 《ACTA HISTOCHEMICA ET CYTOCHEMICA》2014,47(2):67-74
Activated platelets form platelet–leukocyte aggregates in the circulation in inflammatory diseases. We investigated whether activated platelets in inflamed skin tissues are phagocytized and removed by neutrophils. To investigate the kinetics of platelets and neutrophils, we immunohistochemically examined the spatiotemporal distribution of them in a murine model of 2,4,6-trinitro-1-chlorobenzene (TNCB)-induced dermatitis by using confocal and structured illumination microscopy. Four hours after elicitation, aggregates of CD41-positive platelets were adhered to CD31-positive endothelial cells within the vessels, and CD62P and PF4, markers of activated platelets, were expressed on platelet aggregates. At 8 hour post-elicitation, fragmented CD41-positive platelets were located both inside and outside vessels. Twenty-four hours after elicitation, the number of Ly-6G-positive neutrophils ingesting fragmented CD41-positive platelets outside vessels was increased, and CD62P and PF4 expression on the phagocytosed platelets was no longer observed. Disc-shaped CD41-positive platelets were not found outside vessels at any time during the experiment. Our data revealed that aggregates of activated platelets inside vessels were ingested and removed by neutrophils in the early stage of TNCB-induced dermatitis, suggesting that the process of removal of activated platelets by neutrophils may play an important role not only in the early phase of skin inflammation but also in other types of acute inflammation. 相似文献
47.
48.
Risa Tamagawa-Mineoka Naoko Yasuoka Mayumi Ueta Norito Katoh 《Allergology international》2018,67(3):388-391
Background
Topical corticosteroids (TCS) can induce adverse effects, such as skin atrophy. Although TCS can cause increases in intraocular pressure (IOP), the effects of daily TCS use on IOP have not been fully elucidated. We evaluated the clinical doses of TCS and the change in the IOP during the daily treatment of atopic dermatitis (AD).Methods
We collected clinical data on a total of 65 patients who were diagnosed with AD and underwent 2 or more IOP measurements at our hospital.Results
Mean monthly facial steroid volumes of ≤11.8 g and ≤15.0 g of TCS were applied to 90% of the patients aged 2–12 years and those aged ≥13 years, respectively. During the treatment, there were no TCS-related increases in IOP in any patient.Conclusions
Our study suggests that TCS might not cause increases in IOP at the abovementioned doses. However, the IOP of steroid responders is known to be highly responsive to steroids. Therefore, patients who have steroids applied to their eyelids had better undergo regular IOP measurements at ophthalmological clinics. 相似文献49.
Shiratori Y Kato N Yoshida H Nakata R Ihori M Imazeki F Yokosuka O Kawase T Katamoto T Unuma T Nakamura A Ikegami F Hirota K Omata M 《Digestive diseases and sciences》2000,45(3):565-574
Adequate dosing of interferon (IFN) and its cost-effectiveness for sustained virological response were evaluated in relation to viral load and subtype. Prospective analysis of IFN therapy on 326 patients with chronic hepatitis C free from cirrhosis was performed using 9 or 6 million unit (MU) of IFN for six months daily and/or three times a week. Sustained virological response was achieved in 50–94% of patients with 2 × 104 copies/ml (competitive RT-PCR) or <100 × 103 copies/ml (Amplicor monitor) of HCV RNA by 468–1206 MU of IFN, but response was only 0–25% of the patients with 2 × 105.5 copies/ml (competitive RT-PCR) or >200 × 103 copies/ml (Amplicor monitor), even with 468–1206 MU of IFN. A high sustained rate was demonstrated in patients with 100–200 × 103 copies/ml of HCV RNA by 901–1206 MU of IFN, in comparison to that with 900 MU of IFN. Multivariate analysis showed that IFN dose had a significant value for the efficacy of IFN therapy in patients presenting 100–200 × 103 copies/ml of HCV RNA. Cost efficacy analysis indicated that it cost approximately $10,000, $26,000, and $50,000–227,000 for one person-viral eradication in the patients with <100, 100–200, and >200 × 103 copies/ml, respectively. High-dose IFN is only cost effective in patients with intermediate viral loads, and IFN therapy could be recommended in patients with <200 × 103 copies/ml of HCV RNA. 相似文献
50.
We investigated the age-related alterations in nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), parvalbumin and neuronal nitric oxide synthase (nNOS) immunoreactivity of the mouse hippocampal CA1 sector. NGF and BDNF immunoreactivity was unchanged in the hippocampal CA1 pyramidal neurons from 2 to 50-59 weeks of birth. In contrast, a significant increase in the NGF and BDNF immunoreactivity was observed in glial cells of the hippocampal CA1 sector from 40-42 to 50-59 weeks of birth. On the other hand, the number of parvalbumin- and nNOS-positive interneurons was unchanged in the hippocampal CA1 sector during aging processes, except for a significant decrease of nNOS-positive interneurons 2 weeks of birth. Our results indicate that NGF and BDNF immunoreactivity was unaltered in the hippocampal CA1 pyramidal neurons during aging processes. In contrast, a significant increase in the NGF and BDNF immunoreactivity was observed in glial cells of the hippocampal CA1 sector during aging processes. The present study also shows that the number of parvalbumin- and nNOS-positive interneurons was unchanged in the hippocampal CA1 sector during aging processes, except for a significant decrease of nNOS-positive interneurons 2 weeks of birth. These results demonstrate that the expression of glial NGF and BDNF may play a key role for helping survival and maintenance of pyramidal neurons and neuronal functions in the hippocampal CA1 sector during aging processes. Furthermore, our findings suggest that parvalbumin- and nNOS-positive interneurons in the hippocampal CA1 sector are resistant to aging processes. Moreover, our findings suggest that nitric oxide synthesized by the nNOS may play some role for neuronal growth during postnatal development. 相似文献